Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Patients 20 & 21

<< Previous

Bullboard Posts

Next >>

Comment by StevenBirchon Jun 10, 2022 7:30pm

132 Views

Post# 34748645

RE:RE:RE:RE:RE:RE:RE:Patients 20 & 21

Maybe the first question at the AGM should be "why are the numbers presented in such a confusing fashion?"

Eoganacht wrote: On the other hand, 5 of the first 12 phase 2 patients were also removed from the study so who really knows what's going on.

Eoganacht wrote: Maybe they also excluded patient 4 from the phase 1b who had metastatic cancer and would not have been evaluated after 138 days. That would make 20.

DJDawg wrote:
............
My belief is that they are counting the 1b patients in the 20. The wording about "completed all the evaluations" is very suggestive to me that they removed the patient that passed away when making that particular table. That would leave them with 21 patients. Not sure why they did 20 instead of 21.
...............